Amprenavir (Agenerase)

Published January 25, 2001; Updated December 04, 2007
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-03-05
Selected Reference
8. Gulick  RM, Smeaton  LM, D'Aquila  RT, Eron  JJ, Currier  JS, Gerber  JG, Acosta  E, Sommadossi  JP, Tung  R, Snyder  S, Kuritzkes  DR, Murphy  RL; AIDS Clinical Trials Group 373 Study Team.
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis. 2001 Mar;183(5):715-21
[PubMed ID: 11181147]
Abstract:
This prospective, multicenter, open-label study was designed to determine the antiretroviral activity and safety of a 4-drug regimen: 1000 mg indinavir every 8 h with 200 mg nevirapine, 40 mg stavudine, and 150 mg lamivudine, each given twice daily in amprenavir-experienced subjects. The primary end points of the study were the human immunodeficiency virus (HIV) RNA level and CD4 cell count responses. Fifty-six subjects were enrolled and were changed from amprenavir-containing regimens to the 4-drug regimen. Overall, at week 48, 33 (59%) of 56 subjects had HIV RNA levels <500 copies/mL (intent-to-treat analysis, where missing values equal > or =500 copies/mL) and CD4 cell counts increased by 94 cells/mm(3) from baseline. Subjects who had previously taken amprenavir combination therapy were more likely to experience virologic failure than those who had taken amprenavir monotherapy (odds ratio, 7.7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression.